Psychosocial Care in Cancer
MEDICOPSYCHIATRIC DISORDERS (WJ KATON, SECTION EDITOR)
First Online: 09 November 2011 DOI:
Cite this article as: Artherholt, S.B. & Fann, J.R. Curr Psychiatry Rep (2012) 14: 23. doi:10.1007/s11920-011-0246-7 Abstract
Psychosocial care for cancer patients historically has been overlooked as an aspect of quality clinical care. However, several organizations have recently made strong recommendations for inclusion of psychosocial care across the continuum of treatment, from diagnosis, through treatment, into survivorship, and in the palliative stages of care. The evidence base for screening, diagnosis, and effective treatment of psychosocial issues in the context of cancer care is growing. Recent highly relevant research covering major topics in psycho-oncology, including distress, delivery of care, psychoneuroimmunology, and cognitive deficits related to cancer, is reviewed in this article.
Keywords Psycho-oncology Cancer Psychosocial Distress Depression Anxiety Screening Health service delivery Palliative care Biobehavioral Biopsychosocial Psychoneuroimmunology Cognition Chemo brain Chemo fog Delirium References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Adler N, Page A, editors. Cancer care for the whole patient: meeting psychosocial health needs Washington, DC: Institute of Medicine: The National Academies Press. 2008.
This is an excellent, comprehensive, and well-regarded report concerning the importance of psychosocial care across the cancer continuum.
Holland J, Watson M, Dunn J. The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psychooncology. 2011;20:677–80.
• Holland J, Andersen B, Breitbart WS, et al. NCCN clinical practice guidelines in oncology: distress management. 1.2011 Edition: National Comprehensive Cancer Network. 2011.
Updated annually to reflect the current research base, this clinical practice guideline is concise and practical.
Carlson LE, Groff SL, Maciejewski O, Bultz BD. Screening for distress in lung and breast cancer outpatients: a randomized controlled trial. J Clin Oncol. 2010;28:4884–91.
Ryan DA, Gallagher P, Wright S, Cassidy EM. Sensitivity and specificity of the distress thermometer and a two-item depression screen (Patient Health Questionnaire-2) with a ‘help’ question for psychological distress and psychiatric morbidity in patients with advanced cancer. Psychooncology. 2011 Sep 15. doi:
Carey M, Noble N, Sanson-Fisher R, Mackenzie L. Identifying psychological morbidity among people with cancer using the Hospital Anxiety and Depression Scale: time to revisit first principles? Psychooncology. 2011 Sep 14. doi:
Palmer SC, van Scheppingen C, Coyne JC. Clinical trial did not demonstrate benefits of screening patients with cancer for distress. J Clin Oncol. 2011;29:e277–8. author reply e279–280.
van Scheppingen C, Schroevers MJ, Smink A, et al. Does screening for distress efficiently uncover meetable unmet needs in cancer patients? Psychooncology. 2011;20:655–63.
Loscalzo M, Clark KL, Holland J. Successful strategies for implementing biopsychosocial screening. Psychooncology. 2011;20:455–62.
Bultz BD, Groff SL, Fitch M, et al. Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice. Psychooncology. 2011;20:463–9.
Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74.
Thekkumpurath P, Walker J, Butcher I, et al. Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire. Cancer. 2011;117:218–27.
Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47:702–12.
Lo C, Zimmermann C, Rydall A, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28:3084–9.
Robson A, Scrutton F, Wilkinson L, MacLeod F. The risk of suicide in cancer patients: a review of the literature. Psychooncology. 2010;19:1250–8.
Misono S, Weiss NS, Fann JR, et al. Incidence of suicide in persons with cancer. J Clin Oncol. 2008;26:4731–8.
Johnson TV, Garlow SJ, Brawley OW, Master VA. Peak window of suicides occurs within the first month of diagnosis: implications for clinical oncology. Psychooncology. 2011 Jan 24. doi:
Van Cleave JH, Egleston BL, McCorkle R. Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc. 2011;59:34–43.
Rosenstein DL. Depression and end-of-life care for patients with cancer. Dialogues Clin Neurosci. 2011;13:101–8.
Linden W, Girgis A. Psychological treatment outcomes for cancer patients: what do meta-analyses tell us about distress reduction? Psychooncology. 2011 Sep 1. doi:
Battaglini CL. Physical activity and hematological cancer survivorship. Recent Results Cancer Res. 2011;186:275–304.
Duijts SF, Faber MM, Oldenburg HS, et al. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors—a meta-analysis. Psychooncology. 2011;20:115–26.
Ames SC, Tan WW, Ames GE, et al. A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology. 2011;20:435–40.
Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40:1797–810.
Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29:413–20.
Coyne JC, Hanisch LJ, Palmer SC. Psychotherapy does not promote survival (Kissane et al., 2007): now what? Psychooncology. 2007;16:1050–2.
Stefanek ME, Palmer SC, Thombs BD, Coyne JC. Finding what is not there: unwarranted claims of an effect of psychosocial intervention on recurrence and survival. Cancer. 2009;115:5612–6.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.
Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011;29:1029–35.
Taylor S, Harley C, Campbell LJ, et al. Discussion of emotional and social impact of cancer during outpatient oncology consultations. Psychooncology. 2011;20:242–51.
Maguire P. Improving communication with cancer patients. Eur J Cancer. 1999;35:1415–22.
•• Kroenke K, Theobald D, Wu J, et al. Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA. 2010;304:163–171.
This was a randomized controlled study of an innovative and far-reaching collaborative care approach to treating commonly co-occurring symptoms in cancer.
Marcus AC, Garrett KM, Cella D, et al. Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncology. 2010;932:923–32.
DuHamel KN, Mosher CE, Winkel G, et al. Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation. J Clin Oncol. 2010;28:3754–61.
Fann JR, Fan M-Y, Unützer J. Improving primary care for older adults with cancer and depression. J Gen Int Med. 2009;24 Suppl 2:S417–24.
Ell K, Xie B, Kapetanovic S, et al. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv. 2011;62:162–70.
Strong V, Waters R, Hibberd C, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet. 2008;372:40–8.
Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clinics N Am. 2011;31:109–32.
• Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010;28:4094–4099.
This is a comprehensive overview of the research to date on psychoneuroimmunology and biobehavioral factors that may influence cancer progression.
Bower JE, Ganz PA, Irwin MR, et al. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011;29:3517–22.
Fann JR, Hubbard RA, Alfano CM, et al. Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29:895–901.
Zerr DM, Fann JR, Breiger D, et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood. 2011;117:5243–9.
• Janelsins MC, Kohli S, Mohile SG, et al. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38:431–438.
This is an up-to-date overview of the research concerning cognitive dysfunction in the context of cancer.
Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.
Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011;29:2397–404.
Wu LM, Austin J, Hamilton JG, et al. Self-efficacy beliefs mediate the relationship between subjective cognitive functioning and physical and mental well-being after hematopoietic stem cell transplant. Psychooncology. 2011 Jul 8. doi:
Kurita GP, Sjogren P, Ekholm O, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol. 2011;29:1297–303.
Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1–98 trial. Breast Cancer Res Treat. 2011;126:221–6.
Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1294–300.
Mohile SG, Lacy M, Rodin M, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010;75:152–9.
Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5030–7.
• Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010;19:1321–1328.
This was an interesting study highlighting the potential subjective and objective aspects of cognitive dysfunction in cancer patients.
Pullens MJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010;19:1127–38.
Schagen SB, Das E, Vermeulen I. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2011 Jul 18. doi:
© Springer Science+Business Media, LLC 2011